Determinants of Multidrug Resistance Tuberculosis: A Systematic Review and Meta-analysis
Kaleab Tesfaye Tegegne1*, Andualem Zenebe1, Abiyu Ayalew Assefa1, Mekibib Kassa Tessema2, Eleni Tesfaye Tegegne3, Alelign Tadele Abebe4, Berhanu Bifato1 and Muse Rike5
1Department of Public Health, Hawassa College of Health Science, Hawassa, Ethiopia
2Leishmania Research and Treatment Center, University of Gondar, Gondar, Ethiopia
3College of Medicine and Health Science, School of Nursing, University of Gondar, Gondar, Ethiopia
4Department of Medical Laboratory Technology, Hawassa College of Health Science, Hawassa, Ethiopia
5Hawassa College of Health Science, Research and Publication Directorate, Ethiopia
*Corresponding Author: Kaleab Tesfaye Tegegne, Department of Public Health, Hawassa College of Health Science, Hawassa, Ethiopia.
May 15, 2021; Published: May 29, 2021
Objective: The aim of this systemic review and meta-analysis was to determine demographic, behavioral and clinical risk factors for multiple drug-resistant.
19 studies were included in the systemic review and meta-analysis.
Materials and Methods: Search engines: PubMed/Medline, Web of Science, Scopus and Google scholar were used to search related literatures on MDR TB and selected determinates of MDRTB. All data were independently extracted. We used a random-effects model according to the DerSimonian and Laird method
Results: The risk of having MDR-TB in patients who have informal education was 0.67 times lower than that of patients who have formal education (RR = 0.67; 95% CI, 0.46 to 0.96).
The risk of having MDR-TB in patients who have Diabetes Mellitus was 1.33 times higher than that of patients who have no Diabetes Mellitus (RR of 1.33 and 95% CI, 1.01 to 1.77).
Conclusion: This systemic review and meta-analysis indicated that the risk of having MDR-TB in patients who have informal education was 0.67 times lower than that of patients who have formal education and the risk of having MDR-TB in patients who have Diabetes Mellitus was 1.33 times higher than that of patients who have no Diabetes Mellitus.
Our review did not showed the presence of association between MDR TB and other selected variables gender, smoking and alcohol.
We recommend interested researchers on MDR TB to do further research on patient’s educational level as a risk factor for MDR-TB in order to explain the variation in MDR TB among patients with formal education and patients with informal education.
Keywords: Surveillance; Radiation Therapy; Cancer; Breast; Treatment
- Caminero JA. “Guidelines for Clinical and Operational Management of Drug-Resistant Tuberculosis”. Paris, France: International Union Against Tuberculosis and Lung Disease (2013).
- United Nations General Assembly. Resolution 73/3: Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. United Nations (2018).
- Angelo I., et al. “Drug-Resistant Tuberculosis 2020: Where We Stand”. Applied Science Journal6 (2020): 2153.
- World Health Organization. Global tuberculosis report. Geneva: World Health (2017).
- Migliori GB., et al. “Review of multidrug resistant and extensively drug resistant TB: global perspectives with a focus on sub-Saharan Africa”. Tropical Medicine and International Health 15 (2010): 1052-1066.
- Ben AY., et al. “Under reported threat of multidrug-resistant tuberculosis in Africa”. Emerging Infectious Diseases 14 (2008): 1345-1352.
- Daneau G., et al. “The majority of patients with multidrug-resistant tuberculosis in sub-Saharan Africa present a concomitant resistance to pyrazinamide”. International Journal of Microbiology, IJMYCO7 (2016): 2.
- World Health Organization. “Global tuberculosis control report”. 20th ed. Geneva: World Health Organization (2015).
- Faustini A., et al. “Risk factors for multidrug resistant tuberculosis in Europe: a systematic review”. Thorax 61 (2006): 158-163.
- Ejaz M., et al. “Prevalence of multi-drug resistant tuberculosis in Karachi, Pakistan: identification of at risk groups”. Transactions of the Royal Society of Tropical Medicine and Hygiene 104 (2010): 511-517.
- Casal M., et al. “A case control study for multidrug-resistant tuberculosis: risk factors in four European countries”. Microbial Drug Resistance 11 (2005): 62-67.
- Suarez-Garcia I., et al. “Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain”. European Journal of Clinical Microbiology and Infectious Diseases 28 (2009): 325-330.
- World health Organization, International Union Against Tuberculosis and Lung Disease (2007) A WHO/The Union Monograph on TB and Tobacco control, Joining efforts to control two related global epidemics. Geneva (2007).
- Fisher-Hoch SP., et al. “Type 2 diabetes and multidrug-resistant tuberculosis”. Scandinavian Journal of Infectious Diseases 40 (2008): 888-893.
- Abdella K., et al. “Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia”. BMC Public Health1 (2015): 599-609.
- Meskel DW., et al. “Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital”. Ethiopian Medical Journal3 (2008): 219-225.
- Abate D., et al. “Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, Ethiopia”. BMC Research Notes 5 (2012): 462.
- Mesfin EA., et al. “Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multidrug-resistant tuberculosis suspected patients from Ethiopia”. PLoS ONE6 (2018): e0197737.
- Hirpa S., et al. “Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study. BMC Public Health 13.1 (2013): 782.
- Deressa MA and Demissie M. “Risk Factors of Multi-Drug-resistant Tuberculosis in Addis Ababa, Ethiopia: A Matched Case±control Study”. Open Access Library Journal 3 (2014): 1-8.
- Al Jarad N., et al. “Characteristics of patients with drug resistant and drug sensitive tuberculosis in East London between 1984 and 1992”. Thorax 49 (1994): 808-810.
- Murray J., et al. “Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with high prevalence of HIV infection”. South African Medical Journal 90 (2000): 381-386.
- Moher D., et al. “Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement”. PLoS Medicine 6 (2009): e1000097
- World Health Organization. “Definitions and reporting framework for tuberculosis-2013 revision”. Geneva: WHO press (2013).
- G Wells., et al. “The Newcastle-Ottawa Scale (NOS) for assessing the quality of non randomized studies in meta-analyses”. Ottawa Hospital Research Institute, Ottawam, Canada (2009).
- DerSimonian R and Laird N. “Meta-analysis in clinical trials”. Control on Clinical Trials 7 (1986): 177-188.
- Higgins JP., et al. “Measuring inconsistency in meta-analyses”. BMJ 327 (2003): 557-560.
- Review Manager 5 (RevMan 5) [Computer program]. Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration (2014).
- Arnaud Iradukunda., et al. “Keys factors influencing multidrug-resistant tuberculosis: A Mixt Effects Modelling Study in Burundi”. BMC Public Health (2020).
- , et al. “Determinants of multidrug-resistant tuberculosis in Addis Ababa, Ethiopia". Infection and Drug Resistance 10 (2017): 209-213.
- B Baya., et al. “Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali”. International Journal of Infectious Diseases 81 (2019): 149-155.
- Fregona G., et al. “Risk factors associated with multidrug-resistant tuberculosis in Espírito Santo, Brazil”. Revista de Saúde Pública 51 (2017): 41.
- G Mulisa., et al. “Multidrug-resistant Mycobacterium tuberculosis and associated risk factors in Oromia Region of Ethiopia”. International Journal of Infectious Diseases 39 (2015): 57-61.
- Glasauer S., et al. “First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017”. PLoS ONE6 (2019): e0217597.
- Herman Owuor Weyenga. “Factors associated with multi-drug resistant tuberculosis in Kenya”.
- Liang Libo. “Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China”. Thorax 67 (2012): 632-638.
- , et al. “Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachiho, Northwest Ethiopia”. BMC Infectious Diseases 15 (2015): 461.
- Rifat M., et al. “Development of Multidrug Resistant Tuberculosis in Bangladesh: A Case-Control Study on Risk Factors”. PLoS ONE8 (2014): e105214.
- Vashakidze L., et al. “Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia”. International Journal of Tuberculosis and Lung Disease 13 (2009): 1148-1153.
- , et al. “Risk factors for development of multidrug-resistant tuberculosis among relapsed patients in west papua, indonesia: a descriptive and analytical study”. International Journal of Applied Pharmaceutics 11.6 (2019): 50-55.
- Hirama T., et al. “Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010-2016”. Canada Communicable Disease Report 4 (2020): 84-92.
- Barroso Clara E., et al. “Risk factors for acquired multidrug-resistant tuberculosis”. Journal of Pneumologia2 (2003).
- Nigus DM., et al. “Prevalence of Multi Drug Resistant Tuberculosis among Presumptive Multi Drug Resistant Tuberculosis Cases in Amhara National Regional State, Ethiopia”. Mycobacterial Diseases 4 (2014): 152.
- Baghaei P., et al. “Risk Factors Associated with Multidrug-Resistant Tuberculosis”. National Research Institute of Tuberculosis and Lung Disease, Iran Tanaffos 8.3 (2009): 17-21.
- , et al. “Multidrug-resistant tuberculosis and risk factors associated with its development: a retrospective study”. Journal of Infection in Developing Countries 9.10 (2015): 1076-1085.
- Tenzin C., et al. “Factors associated with multidrug-resistant tuberculosis (MDR-TB) in Bhutan: A nation wide case-control study”. PLoS ONE 7 (2020): e0236250.
- Lema N., et al. “Risk factors associated with multidrug resistant tuberculosis among patients referred to Kibong’oto Infectious Disease Hospital in northern Tanzania”. Tanzania Journal of Health Research4 (2016).
- , et al. “Risk factors associated with multidrugresistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia”. BMC Infectious Diseases 18 (2018): 249.
- , et al. “Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia”. BMC Public Health 18 (2018): 422.